Immunglobulınler ve Myastenia Gravıs: Geleneksel Derleme
Öz
Myasthenia Gravis is an autoimmune disease characterised by the development of antibodies against proteins in the neuromuscular junction, resulting in complaints such as fatigue and muscle weakness. Quality of life is adversely affected due to complaints such as droopy eyelids (ptosis), blurred or double vision, difficulty in speaking, difficulty in swallowing and breathing. It causes morbidity and mortality due to myasthenic crisis and subsequent complications. Intravenous immunoglobulin therapy, plasmapheresis, anticholinesterase drugs, immunosuppressant drugs or thymectomy surgery can be applied in the treatment of myasthenia gravis, which can lead to serious permanent damage and rarely fatal consequences. Treatment preference varies according to the course of the disease. In this review, pharmacokinetics, administration procedures, adverse events, patient variables and cost considerations of intravenous immunoglobulin (IVIg) in myasthenia gravis will be discussed.
Anahtar Kelimeler
Kaynakça
- 1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest, 2006, 116: 2843-2854.
- 2. Linstrom J, Seybold M, Lennon V, Wittingham S, Drake D. Antibody to acetylcoline receptor in myasthenia gravis. Neurology, 1976, 26: 1054-1059.
- 3. Marx A, Willcox N, Leite M, Chuang W-Y, Schalke B, Nix W, Ströbel P. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity, 2010, 43: 413-427.
- 4. Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity, 2010, 43: 371-379.
- 5. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med, 2001, 7: 365-368.
- 6. Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Current opinion in neurology, 2010, 23: 530-535.
- 7. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis. Ann Neurol, 2011, 69: 418-422.
- 8. Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR, Detmers FJ, Hermans PW, Sleijpen K, Verrips A, Losen M. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain, 2012, 135: 1081-1101.
- 9. Viegas S, Jacobson L, Waters P, Cossins J, Jacob S, Leite MI, Webster R, Vincent A. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol, 2012, 234: 506-512.
- 10. Sanders D, Howard J. chap. 82: Disorders of neuromuscular transmission. Neurology in Clinical Practice, Elsevier Health Sciences, Philadelphia, 2008: 2383-2394.
